UCB - Sales Revenues



UCB reported EUR3.49B in Sales Revenues for its fiscal semester ending in June of 2025.


Sales Change Date
Alcon AG USD 2.58B 130M Jun/2025
Almirall EUR 275M 9.6M Jun/2025
Amarin USD 72.74M 30.72M Jun/2025
argenx SE USD 842.5M 132.26M Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Bayer EUR 10.74B 3B Jun/2025
Galapagos EUR 70.17M 4.81M Jun/2025
Genmab DKK 5.86B 580M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
GRIFOLS EUR 1.89B 100M Jun/2025
Hikma Pharmaceutical USD 1.59B 18M Dec/2024
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 4.43B 850M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Orion EUR 416.5M 61.9M Jun/2025
Recordati EUR 643.15M 36.81M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 9.99B 90M Jun/2025
UCB EUR 3.49B 129M Jun/2025
Unibail Rodamco EUR 1.21B 447.65M Dec/2024